Introduction
Fungal pathogens are a serious emerging infectious disease threat and are the target of efforts to develop novel vaccines. The rising danger of mycoses is compounded by both the paucity and toxicity of the pharmacological armamentarium available to treat these infections and the immunocompromised status of the large majority of patients with fungal infections. While fungi are commonly encountered by humans in their environment, particularly as inhaled spores or conidia, few fungal species are human pathogens. Fungi also exist as useful commensal organisms until the host becomes immunodeficient or a systemic portal like a venous catheter is colonized, whereupon commensal fungi can cause life-threatening infections. Thus, the development of fungal vaccines faces the dual challenge of providing protection to immunocompromised patients and protection against primary pathogens that cause lethal infections in healthy individuals.
The rising incidence of fungal infections is linked to the increase in immunocompromised individuals, specifically, patients with AIDS, patients with cancer, and recipients of solid organ or hematopoietic stem cell transplants. Candida species are the second leading cause of infectious disease-related death in premature infants and the fourth leading cause of hospital bloodstream infections (Benjamin et al., 2010; Pfaller and Diekema, 2007) . A rise in the incidence of zygomycosis is also noted in patients with diabetes mellitus (Bitar et al., 2009) , augmenting clinical challenges in this growing patient population. Major endemic mycoses can lead to lethal systemic infections in apparently healthy individuals and can reactivate in the setting of immune suppression. Also, fungal-associated allergy and asthma contribute significantly to the human health burden due to fungi.
Encounters with fungi require a coordinated host innate and adaptive immune response to successfully eradicate the fungus and to promote long-lived immunological memory of the encounter. Iatrogenic risk factors for fungal infections such as granulocytopenia, compromised mucosal barriers, and T cellsuppressing drugs demonstrate important roles for both innate and adaptive responses to fungi. In fungal infections, both CD4 + and CD8 + T cells participate in the elimination of the pathogen (Cutler et al., 2007) . Most fungi also elicit antibodies, some of which are protective and can neutralize fungal pathogens or promote fungal uptake by phagocytes (see accompanying review by Casadevall and Pirofski [2012] ). Phagocytes and other innate immune cells play a critical role in combating fungal pathogens (reviewed by Brown, 2011) . Activated phagocytes and neutrophils kill fungi either following phagocytosis or via the production of fungicidal chemicals, including reactive oxygen and nitrogen species. Epithelial cells also produce fungicidal compounds such as b-defensin and provide a mechanical barrier at mucosal sites exposed to fungi. Expectedly, genetic or acquired deficiency in either the innate or adaptive immune response significantly increases the risk of fungal infection. For example, individuals with an early stop codon mutation in Dectin-1 suffer recurrent mucocutaneous fungal infections (Ferwerda et al., 2009) whereas Pneumocystis pneumonia is a frequent AIDS-defining diagnosis (Huang et al., 2011) .
At the intersection of innate and adaptive immunity are dendritic cells (DC), unique cells capable of taking up and processing antigen for presentation by major histocompatibility complex (MHC) class I or MHCII molecules to naive T cells and also themselves possessing potent fungicidal activity. DC recognize fungi via a broad array of surface and intracellular pattern recognition receptors (PRR). Recognition of fungi results in the secretion of cytokines by DC and the expression of costimulatory molecules on the DC surface, both of which are required to drive naive CD4 + T cell differentiation into a T helper (T h ) phenotype. Clearance of fungi with limited damage to the host requires a finely tuned balance between T h 1, T h 17, and T reg subsets; the precise response needed is based on the anatomical location and the specific fungal pathogen. DC calibrate and orchestrate the balance of helper, regulatory, and effector T cell responses, thus integrating innate and adaptive immune responses to fungi. The unique ability of DC to initiate and engage antifungal immunity positions them as logical cellular targets for the development of fungal vaccines. In this review, we describe the panoply of DC subsets and their function in antifungal immunity, identify how DC recognize fungi, and discuss strategies to target DC in the development of novel antifungal vaccines. We emphasize DC subsets using murine surface markers; corresponding human DC subset markers continue to be elucidated and are reviewed elsewhere (Naik, 2008) .
Characterization and Function of DC and Monocyte Subsets
Four decades ago, Steinman and Cohn reported the identification of a cell with ''continually elongating, retracting, and reorienting'' long cytoplasmic processes in the spleen and lymph nodes of mice (Steinman and Cohn, 1973) . These cells, now known as DC, are hematopoietic cells that function as professional antigen-presenting cells and that are capable of initiating a T cell response. When DC encounter antigen at the boundary of immunological defense sites such as the skin or the airways of the lung or in the draining nodes of the lymphatic system, DC amplify the innate immune response by secreting cytokines that recruit and activate other leukocytes. Following engulfment, processing, and presentation of the antigen, DC initiate and shape adaptive responses by promoting naive T cell differentiation into effector or regulatory T cells. Since their discovery, a plethora of DC subsets characterized by anatomical location, function, and surface marker expression have been described (Figure 1 ). Indeed, it is the specialized functions of the diverse DC subsets that augment the challenge of targeting DC in the development of antifungal vaccines. Therefore, ongoing efforts to characterize the function of DC subsets will enhance the rational design of DC-targeted antifungal vaccines. DC subsets and monocytes arise from a common precursor in the bone marrow. pDC, monocytes, and PreDC exit the bone marrow and circulate via the blood. Resident CD8 + and CD8 -DC exist in the spleen and the lymph node. PreDC seed the lungs, skin, and intestine and give rise to DC subsets in those locations. Migratory DC subsets migrate from peripheral locations to draining lymph nodes where they interact and prime T cells. In the lungs, CD103 + DC sample antigen from the airway lumen via paracellular processes. CD11b + DC and CD103 + DC migrate to mediastinal lymph nodes. The epidermis of the skin contains a unique DC subset, Langerhans cells (LC), that are seeded in utero and self-renew. LC sample antigen and migrate via the dermis to skin-draining lymph nodes. Dermal DC also migrate to skin-draining lymph nodes. In the intestine, DC exist in the Peyer's Patch (PP) and the lamina propria (LP). PP-DC sample antigen-using transcellular processes from the intestinal lumen, following which they migrate to the T cell-rich area of the PP, where PP-DC prime T cells. LP-DC subsets migrate to the mesenteric lymph node following antigen sampling. During inflammation, monocytes enter inflamed tissue and differentiate into monocyte-derived DC (Mo-DC), which then carry antigen to draining lymph nodes.
In the steady state, monocytes and DC share a common progenitor cell in the bone marrow, the macrophage-dendritic cell progenitor (MDP) (Fogg et al., 2006; Liu et al., 2009) . From the MDP, a common-DC progenitor and monocytes are produced. The common-DC progenitor (CDC), which is restricted to the bone marrow gives rise to three broad groupings of DC: plasmacytoid DC (pDC), conventional DC, and migratory DC. While monocytes and pDC mature in the bone marrow and are released into the blood for circulation to lymphoid tissues, resident and migratory DC precursors, known as preDC, exit the bone marrow and circulate via the blood before either entering the high endothelial venules of lymphoid tissues or seeding peripheral tissues. Plasmacytoid DC pDC are typified by their high production of interferon-a (IFN-a) in response to the sensing of nucleic acids by endosomal Toll-like receptors and are further characterized in part by the high surface expression of sialic acid binding immunoglobulin-like lectin H (Siglec H). Using a Siglec H-DTR depleter mouse, a recent study further elucidated the roles of pDC in vivo (Takagi et al., 2011 (Dudziak et al., 2007) .
Relative to other pathogen classes such as viruses, information regarding the role of resident DC in priming T cell responses to fungi is limited. Direct evidence that resident DC prime antifungal T cell responses was demonstrated in a vaccine model to generate immunity to Blastomyces dermatitidis. Lymph node resident DC acquired and displayed antigen and primed antigen-specific CD4 + T cells, however acquisition of the antigen depended on ferrying of the yeast from the skin to the lymph node by migratory and monocyte-derived DC (Ersland et al., 2010) . Less is known about cross-presentation of fungal antigens in vivo. Bone marrow-derived DC acquire and crosspresent Histoplasma capsulatum antigens to CTL via ingestion of live or killed Histoplasma capsulatum yeasts or via engulfment of Histoplasma containing apoptotic macrophages (Lin et al., 2005) . Subcutaneous injection of apoptotic phagocytes containing CFSE-labeled heat-killed Histoplasma results in the accumulation of CFSE in CD11c + cells in skin-draining lymph nodes and CD11c + -dependent CTL-mediated protection against
Histoplasma challenge (Hsieh et al., 2011) . While these studies provide evidence that fungal antigens can be acquired and presented by resident DC, the precise resident DC subpopulation or subpopulations involved in vivo remain undefined. Unexpectedly, CD4 + CD8 -resident DC may be important for the cross-presentation of fungal antigens. In experiments using an OVA-expressing strain of the model yeast Saccharomyces cerevisiae, both CD8 + and CD4 + CD8 -DC isolated from mouse spleen and primed with OVA-S. cerevisiae induced robust OVA-specific CD4 + T cell proliferation ex vivo, however only CD4 + CD8 -DC stimulated an OVA-specific CD8 + T cell response (Backer et al., 2008) . To that end, further studies will be needed to unravel the specific contributions of resident DC subpopulations to CD4 + T cell and CTL activation and polarization in vivo.
Migratory DC Migratory DC, also referred to as tissue DC, are immature DC that are located principally in peripheral tissues such as the skin, the lung, and the gut. Following uptake of antigen, migratory DC exit the tissue and undergo maturation characterized by (1) enhanced antigen processing and presentation, (2) downregulation of tissue homing receptors, (3) upregulation of CCR7, and (4) increased surface expression of costimulatory molecules. CCR7 + DC migrate to the T cell zone of lymphoid tissue, where they can initiate activation of naive T cells or transfer antigen to resident DC (Banchereau and Steinman, 1998; Allan et al., 2006) . With the exception of Langerhans cells in the epidermis, the majority of migratory DC appear to derive from the same circulating precursor as conventional DC, the preDC. Migratory DC have some capacity for division and self-renewal in situ, while monocyte subsets also contribute to replenishment of migratory DC in certain circumstances. Migratory DC line the surfaces of the body that are exposed to the environment and, as such, are likely to encounter fungi along with other pathogens and antigens. While the migratory DC networks that line the skin, lung, and intestine share similarities, each site has functional differences that are important in antifungal immunity and deserve individual discussion. Skin The skin is lined by a dense network of DC which can be broadly divided into the epidermis-associated Langerhans cell (LC) and a collection of dermis-associated dermal DC (Henri et al., 2010a) . LC are unique among migratory DC as they arise from a MDP-like cell seeded into the epidermis in utero followed by a wave of expansion within days of birth (Chorro et al., 2009) . In addition to their epidermal location, LC are characterized by surface expression of the eponymous langerin (CD207), CD11c, and MHCII. The dermis contains LC that migrate to the draining lymph node, CD207 + CD103 + dermal DC, and a diverse group of CD207 -CD103
-DC (Henri et al., 2010b) . Upon subcutaneous administration of a B. dermatitidis vaccine, DEC205 expressing skin-derived DC migrated to the skin-draining lymph node in a CCR7-dependent fashion, presented the model antigen expressed by the fungus, and activated CD4 + T cells (Ersland et al., 2010 (Desch et al., 2011) . CD11b + DC differ from monocyte-derived DC and specialize in cytokine and chemokine production (Beaty et al., 2007) , as well as presenting antigen via MHCII to CD4 + T cells in the mediastinal lymph node following migration (del Rio et al., 2007) . Rapid recruitment of Ly6C + monocyte-derived DC to the lung upon inflammation clouds analysis of the function of lung CD11b + DC, which lack Ly6C surface expression.
Upon pulmonary exposure to A. fumigatus conidia, CD103 + DC failed to take up and transport conidia to the mediastinal lymph node, whereas CD11b + DC did transport them (Hohl et al., 2009 ). In this model, lung CD11b + DC were reduced relative to wildtype mice in CCR2 À/À mice following A. fumigatus exposure.
Conversely, naive CCR2 À/À mice had similar lung CD11b + DC numbers to wild-type mice, suggesting that recruited monocyte-derived DC (discussed in detail later in this review) and not lung CD11b + DC are responsible for conidial uptake and antigen presentation in the setting of A. fumigates-induced inflammation. Intestine Just like the lung, DC in the intestine are situated on the basolateral side of the epithelial layer largely isolated from the gut microflora. DC in the intestine localize to two major subepithelial locations, the lamina propria and the Peyer's patch; both subsets in each region differentially regulate immune responses. The Peyer's patch is a specialized structure that consists of organized T and B cell follicles capped by a unique epithelial cell dome called an M cell. Peyer's patch DC (PP-DC) extend dendrites through M cells to sample antigen from the intestinal lumen. This transcellular method of antigen sampling appears to be distinct from the paracellular sampling that occurs in the lung and outside of the PP in the intestine (Lelouard et al., 2012) . Following antigen internalization, PP-DC migrate to the T cell-rich zone of the PP to prime naive T cells.
Lamina propria DC (LP-DC) express CD11c, MHCII, and CD103 and can be further divided into CD11b + and CD11b -subsets. CD11b + and CD11b -LP-DC subsets represent two sides of an equilibrium that maintain the balance between the induction of T h 17 and T reg responses, respectively, in the intestinal wall (Denning et al., 2011) . Indeed, CD11b
+ LP-DC numbers are elevated in the duodenum and gradually decrease throughout the small intestine and reach their lowest levels in the colon, mirroring the distribution of T h 17 cells. LP-DC play distinct roles in directing CD4 + T cell differentiation in the lamina propria dependent on the local LP-DC to T cell ratio and DC-T cell location along the intestine. Furthermore, the gut microbiota plays a key role in shaping the function of these subsets, as LP-DC from mice obtained from separate vendors display strikingly different efficiencies at priming T h 17 cells based in part on the presence or absence of segmented filamentous bacteria (Sczesnak et al., 2011) . In addition to their ability to affect T cell responses locally in the intestine, both subsets of LP-DC The role of PP-DC and LP-DC in generating antifungal immunity in the gut is unclear and relatively unstudied. C. albicans, a gut commensal fungus, can cause systemic infection if the gut epithelial/DC barrier is substantially breached and/or in the setting of broad-spectrum antibiotic use leading to Candida overgrowth. Strong induction of T reg cells by LP-DC in the mesenteric lymph node may highlight the critical role of limiting inflammation in the gut in order to maintain the epithelial barrier and prevent disseminated infection. Furthermore, heightened T h 17 responses in the gut impair protective T h 1 responses and worsen Candida infection (Zelante et al., 2007) . While bone marrow-derived DC produced IL-23 in response to Candida in vitro and IL-23 neutralization promoted fungal clearance in vivo, the identity of the DC subset recognizing and responding to the fungus in this model was not determined. Nevertheless, DC in the gut appear to tightly control tolerance and immunity to fungal organisms. Monocytes, Monocyte-Derived DC, and Inflammatory DC Monocytes are derived from the MDP and, in the absence of inflammation, are found in the bone marrow and circulating at low levels in the blood and spleen. (Ersland et al., 2010) . Thus, in the setting of the lung, which is the primary route of infection for fungi, but not the skin or the spleen, monocyte-derived DC appear to play a critical role in antifungal immunity .
Fungal Recognition by DC
Recognition of fungi by DC is accomplished by a diverse group of PRR that recognize conserved fungal PAMP, including proteins, carbohydrates, and nucleic acids (Figure 2 ). Antifungal immunity depends critically on the recognition of fungi by PRR. Fungal recognition by PRR induces intracellular signaling pathways that lead to DC maturation and secretion of cytokines that instruct the evolving immune response. PRR can also mediate the uptake of fungi by DC and can direct fungi to appropriate intracellular compartments for antigen processing and subsequent presentation. PRR important for the recognition of fungi include Toll-like receptors (TLR) and C-type lectin receptors (CLR), which can respond individually or synergistically to fungi. Other fungal PRR include scavenger receptors, such as SCARF1 and CD36, that can mediate binding to C. neoformans (Means et al., 2009 ) and complement/Fc receptors, which recognize complement factor or antibody-coated fungi directly (Taborda and Casadevall, 2002) and mediate phagocytosis. TLR Recognition of PAMP by TLR results in engagement of intracellular signaling pathways culminating in the activation of the transcription factors activator protein-1 (AP-1) and nuclear factor-kB (NF-kB). All TLR transmit their PAMP recognition event via TIR-mediated engagement of myeloid differentiation primary response gene 88 (MyD88) with the exception of TLR3, which recruits the adaptor TIR-domain containing adaptor-inducing IFN-beta (TRIF). A subset of TLR are also able to activate interferon regulatory factor 3 (IRF3) or IRF7 which regulate the expression of type I IFN. Since MyD88 is instrumental in priming T h 1 cells in response to fungi (Rivera et al., 2006) , it is generally thought that fungal recognition by TLR induce a T h 1 response. The role of TLR for the induction of antifungal T h 17 cells is less clear. By using naive fungus-specific T cell receptor transgenic cells, a recent study demonstrated that TLR-induced MyD88 activity, and not dectin-1 or IL-1R signaling, was required for the development of vaccine-induced T h 17 cells and resistance to B. dermatitidis infection (Wü thrich et al., 2011) . The identity of the TLR driving this response is unknown. TLR are globally expressed on DC, although some subsets of DC may express only a subset of TLR. For example, TLR3 is expressed 28-fold more by CD8 + DC than by CD4 + CD8 -DC in the spleen (Edwards et al., 2003) , suggesting that DC subsets are differentially activated by discrete fungal TLR ligands. TLR2 While TLR-mediated signaling in DC generally favors the development of T h 1 responses, TLR2 signaling may promote nonprotective T h 2 or T reg differentiation. TLR2-mediated recognition of C. albicans results in increased IL-10 production and a concurrent decrease in T h 1 polarization (Netea et al., 2004) . As a result, TLR2 À/À mice showed increased resistance to disseminated candidiasis that was associated with increased IL-12 and IFN-g and decreased IL-10 production. Further evidence for the antiinflammatory role of TLR2 signaling in DC was provided by two additional studies. First, DC recognition of zymosan via TLR2 and dectin-1 promoted T reg cell differentiation via IL-10 and TGF-b secretion (Dillon et al., 2006) . Second, live A. fumigatus hyphae reduced IL-12 and IL-23 production and increased IL-10 production from DC exposed to house dust mite extract in a TLR2 and dectin-1 dependent fashion, suggesting that TLR2 recognition of fungal ligands may promote tolerance rather than protective immunity. TLR4 Recognition of fungal ligands by TLR4 similarly engenders heterogeneous responses that fail to recapitulate TLR4-mediated responses to the prototypical TLR4 ligand LPS. For example, recognition of C. albicans-derived O-linked mannosyl residues by TLR4 promotes proinflammatory cytokines. By contrast, TLR4 binding of the C. neoformans cell wall component glucuronoxylomannan (GXM) does not induce cytokine production despite inducing NF-kB nuclear translocation. As TLR4 signaling in response to LPS requires the assembly of a larger complex consisting of CD14 and MD-2, it is likely that fungal recognition by TLR4 will require accessory signaling molecules that may mediate disparate TLR4-mediated responses to different fungal PAMP.
TLR3, TLR7, and TLR9
Multiple studies have demonstrated that fungi are recognized by the endosomal nucleic acid sensing TLR: TLR3, TLR7, and TLR9. For instance, cryptococcal DNA triggered IL-12p40 and CD40 expression in murine DCs and activated NF-kB in TLR9-transfected HEK239 cells (Nakamura et al., 2008) . Similarly, A. fumigatus DNA stimulated the production of proinflammatory cytokines in mouse and human DC (Ramirez-Ortiz et al., 2008) . Drug-resistant Candida glabrata represents an important emerging opportunistic infection. A recent study demonstrated that C. glabrata induces Type I IFN secretion from DC in a TLR7-dependent, but TLR2-and TLR4-independent, manner (Bourgeois et al., 2011) . TLR9 is often targeted with synthetic oligonucleotides that act as strong adjuvants in new vaccine designs. As more is learned about fungal recognition by these TLR and the responses they engender by DC, fungal ligands may provide additional tools to promote antifungal vaccine immunity. CLR Like the TLR, CLR recognize a broad range of PAMP present on fungi. CLR recognize glucan-, mannose-, or fucose-containing structures on fungi and trigger intracellular signaling via ITAMcontaining adaptor molecules leading to maturation of DC and the secretion of cytokines. DC express a wide range of CLR, although expression of some CLR are restricted to a particular 
Dectin-2 and Mincle
While dectin-1 recognizes b-glucan, dectin-2 and Mincle recognize mannose-like structures and require the adaptor FcRg to signal via Syk. Dectin-2 is most abundantly expressed on inflammatory monocytes and DC. Recognition of a-mannans by dectin-2 induces the secretion of IL-2, IL-10, and TNF-a by DC in vitro (Robinson et al., 2009) . Furthermore, in a model of systemic C. albicans infection, dectin-2 À/À mice or mice treated with a dectin-2 neutralizing mAb failed to develop Candidaspecific T h 17 cells. Mincle also induces the production of TNF-a, CXCL1, CXCL2, and IL-10 via Syk and CARD9 upon recognition of C. albicans, Malassezia species, and Fonsecaea pedrosoi, yet whether Mincle engagement on DC by fungal PAMP promotes antifungal immunity remains to be investigated (Sousa et al., 2011) . Mincle, which also recognizes a mycobacterial glycolipid, is already the target of novel vaccine designs against mycobacterial pathogens and may prove to be a fruitful target in antifungal vaccination efforts.
The Mannose Receptor
The mannose receptor (CD206) is a transmembrane protein that binds terminal mannose, N-acetyl glucosamine, or fucose sugars and that lacks classical signaling motifs. It can also be cleaved from the cell surface and exists as a soluble receptor in some circumstances. In response to fungal N-linked mannans, CD206 can induce NF-kB activation and the production of IL-12, GM-CSF, . CD206 also appears to be responsible for the formation of a novel DC phagocytic structure called the ''fungipod'' which may promote yeast phagocytosis by DC and play an important role in DC-fungi interactions (Neumann and Jacobson, 2010) . The role of CD206 in promoting fungal antigen uptake, processing, and presentation by DC remains poorly understood. However, due to the wide expression of CD206 on DC subsets, strategies to target vaccine antigen to CD206 could result in broad DC mobilization and potentially robust vaccine immunity. NLR Recently, a NOD-like receptor family member was found to play a role in the antifungal immunity. Exposure of monocytes to C. albicans germ tubes or A. fumigatus hyphae activated the NLRP3 inflammasome in a Syk-dependent fashion (Hise et al., 2009; Saïd-Sadier et al., 2010) . NLRP3 is activated by a wide range of pathogen-and host-associated stimuli, and it is unclear if NLRP3 senses stimuli directly or indirectly. b-glucan also activates the NLRP3 inflammasome in DC, although this activation is dispensable for antigen specific T h 1 and T h 17 polarization (Kumar et al., 2009) . Fungal structures recognized by NLRP3 may include surface carbohydrates, fungal DNA, or a fungalinduced host factor signifying tissue damage such as ATP. NLRP3 agonists such as aluminum hydroxide have been in use as vaccine adjuvants for decades; thus discerning the mechanism of fungal-induced NLPR3 activation could enhance future vaccine designs against fungi and other pathogens.
Fungal Vaccine Strategies Targeting DC
Only a single clinical trial evaluating efficacy of a fungal vaccine has been completed in humans (Pappagianis, 1993) . A new interest in fungal vaccine development has accompanied the growing knowledge illuminating the critical determinants of host defense against fungal pathogens. More importantly, recent work suggests that it may be possible to create an antifungal vaccine that grants protection against multiple fungal pathogens ( Wü thrich et al., 2011; Stuehler et al., 2011; Cassone and Rappuoli, 2010) . At the core of host resistance to fungi, is the induction of strong cellular immunity via appropriate activation of DC. Antiviral and antitumor vaccine strategies have leveraged the central role of DC in driving CTL responses by first priming autologous monocyte-derived DC with the desired antigen ex vivo before readministering the loaded DC to the host. In animal models, DC primed with fungi ex vivo promote antifungal immunity in naive mice. Similarly, DC transfected with fungal RNA ex vivo express fungal proteins on their surface and promote the development of protective T cell responses (Bozza et al., 2004) . These procedures are time-consuming and expensive, and for those reasons they are unlikely to be widely adopted in clinical medicine. However, recent technological advances in antigen delivery, combined with a greater understanding of DC biology, should allow for effective targeting and loading of DC with immunogenic antigen in vivo.
Because of the dense network of DC in the skin, the lung, and the intestine, vaccine delivery systems that target these DC networks may be more potent (Figure 3) . Indeed, when comparing influenza vaccine injection routes, intradermal injection was more than twice as potent at eliciting antibodies than subcutaneous administration in individuals between 18 and 60 years of age (Belshe et al., 2004) . A current Phase I clinical trial expected to be completed in early 2012 is evaluating the safety of intravaginal application of a virosome-based recombinant Sap2 therapeutic vaccine against recurrent vulvovaginal candidiasis (VVC) (NCT01067131). Preclinical trials in mice demonstrated rapid clearance of Candida and protection from reoccurrence in a murine VVC model following intravaginal administration of the vaccine (Sandini et al., 2011) . However, vaccination at these DC-rich sites may not represent a universal approach to vaccination against fungi. For example, a live attenuated strain of B. dermatitidis engendered full protection when administered subcutaneously, but not when administered intranasally against a lethal pulmonary challenge in mice (Wü thrich et al., 2000 . Correspondingly, CCR2
À/À mice lacking monocyte-derived inflammatory DC had impaired clearance of A. fumigatus from the lung but not the spleen, demonstrating an organ-specific role for this DC subset (Hohl et al., 2009 ). The tissue microenvironment also modulates the function of DC subsets and influences the ability of DC to prime effective T cell responses. DC subsets in the spleen are able to drive T h 17 differentiation in the absence of IL-6, whereas DC from the skin and the gut require IL-6 to drive T h 17 polarization (Hu et al., 2011) . This suggests that the effect of local cytokine generation will need to be factored into fungal vaccine design when considering a route of vaccination. Thus, the DC subtypes and the tissue microenvironment at the vaccination site may critically modulate vaccine responses to fungal antigens. A more direct method to target DC is to covalently attach antigen to DC-specific ligands. Fungal pathogens contain substantially mannosylated proteins which are effectively endocytosed by DC via CLR. In fact, mannosylation of the model antigen OVA greatly enhanced its immunogenicity at least in part by increasing its uptake by DC via CLR family members CD206 and DC-SIGN (CD209) (Lam et al., 2007) . Other fungal carbohydrates also effectively target antigen to DC. For example, antigen-loaded b-glucan particles are actively taken up by DC in a dectin-1 dependent manner. OVA-laden b-glucan particle-exposed DC were more potent at inducing proliferation of OVA-specific CD4 + and CD8 + T cells in vitro compared with soluble OVA (Huang et al., 2010) . Furthermore, subcutaneous administration of OVA-laden b-glucan particles induced higher OVA-specific T cell polarization toward a T h 1 and T h 17 phenotype than alum-adsorbed OVA and induced the secretion of OVA-specific T h 1-associated IgG2c antibodies. Incredibly, fungi themselves are now being exploited to take advantage of direct targeting and robust activation of DC via the b-glucan/dectin-1 interaction. In whole recombinant yeast immunization, antigenexpressing S. cerevisiae yeast (which display b-glucan on their surface) are administered with the goal of eliciting antigenspecific host CD4 + and CD8 + T cell responses (Stubbs et al., 2001) . Completed Phase I trials indicate that S. cerevisiae-based therapies are safe and well tolerated in humans, and Phase II trials are currently ongoing (NCT00124215).
A complementary approach to whole recombinant yeast immunization involves the use of nanoparticles in targeting antigen to DC. Nanoparticles are internalized preferentially by DC due to their submicron size and can be more specifically targeted to DC through the addition of DC receptor (such as Dec 205)-targeting antibodies or DC receptor ligands to their surface. Nanoparticle-mediated targeting of DC enables the bundling of defined antigen or antigens with an adjuvant and a DC receptor-targeting molecule allowing for precise delivery to DC. The elegance of this approach was recently demonstrated using a DEC205 F(ab')2 fragment-coated nanoparticle containing TLR3, TLR7, and TLR8 ligands and OVA antigen (Tacken et al., 2011) . This nanoparticle was designed to target DEC205 + DC and to simultaneously deliver the antigen and TLR ligand adjuvant. Targeting of the particles to DC enhanced their immunogenicity, encapsulating the antigen (OVA) increased the potency of the antigen, and codelivering TLR ligands blocked the development of tolerance and reduced overall toxicity. In total, the study suggests that nanoparticles can deliver vaccine antigen to DC effectively, and that when antigen and adjuvant are delivered together, strong immune responses with limited toxicity can be induced. In a limited way, the targeting nanoparticle loaded with antigen and adjuvant begins to resemble the microbial vaccine target itself.
Since the surfaces of fungi are covered in polysaccharide, carbohydrate, or glycoconjugate antigens, they are attractive targets for antifungal vaccine development. Vaccine strategies based on both the glucuronoxylomannan component of the cryptococcal polysaccharide capsule and b-1,3-glucan that is expressed by a broad range of fungi have demonstrated the ability to promote antibody-mediated protection against fungal challenge. However, immunogenicity of glycoconjugates is unpredictable, and the carbohydrate moiety is thought unable to be recognized by T cells directly. Novel findings using a defined glycoconjugate suggest that it is possible to design vaccines where T cells recognize the carbohydrate directly and that such glycoconjugates greatly enhance immunogenicity (Avci et al., 2011) . It is tantalizing to speculate that fungal carbohydrates displayed by MHC II could be recognized by T cells in the same way. Immunization with glycosylated peptides was able to generate carbohydrate-specific CTL responses (Abdel-Motal et al., 1996) , suggesting that appropriately designed glycoconjugates may be processed and crosspresented to CD8 + T cells. As knowledge of cross-presentation by DC increases, it may be possible to generate fungal carbohydrate specific CTL responses against fungal pathogens. This may be advantageous in immune-deficient patients lacking CD4 + T cells, where CD8 T cells compensate and mediate lasting vaccine-induced resistance to pathogenic fungi (Nanjappa et al., 2012) .
Conclusions
In this review, we have highlighted the role of diverse DC subsets in antifungal immunity and discussed potential strategies to target DC in the generation of novel antifungal vaccines. Vaccines may be targeted to DC via interactions with surface receptors or via other routes of administration and activate DC through PRR. New vaccine construction technologies are expanding the available pool of fungal antigens that induce cell-mediated immunity to include carbohydrates and reduce toxicity. Continuing to unearth the central role of DC in antifungal immunity will suggest new avenues for the development of effective antifungal vaccines.
